Noninferiority of Miltefosine Versus Meglumine Antimoniate for Cutaneous Leishmaniasis in Children
Open Access
- 11 January 2012
- journal article
- research article
- Published by Oxford University Press (OUP) in The Journal of Infectious Diseases
- Vol. 205 (4) , 684-692
Abstract
Background. Children have a lower response rate to antimonial drugs and higher elimination rate of antimony (Sb) than adults. Oral miltefosine has not been evaluated for pediatric cutaneous leishmaniasis. Methods. A randomized, noninferiority clinical trial with masked evaluation was conducted at 3 locations in Colombia where Leishmania panamensis and Leishmania guyanensis predominated. One hundred sixteen children aged 2–12 years with parasitologically confirmed cutaneous leishmaniasis were randomized to directly observed treatment with meglumine antimoniate (20 mg Sb/kg/d for 20 days; intramuscular) (n = 58) or miltefosine (1.8–2.5 mg/kg/d for 28 days; by mouth) (n = 58). Primary outcome was treatment failure at or before week 26 after initiation of treatment. Miltefosine was noninferior if the proportion of treatment failures was ≤15% higher than achieved with meglumine antimoniate (1-sided test, α = .05). Results. Ninety-five percent of children (111/116) completed follow-up evaluation. By intention-to-treat analysis, failure rate was 17.2% (98% confidence interval [CI], 5.7%–28.7%) for miltefosine and 31% (98% CI, 16.9%–45.2%) for meglumine antimoniate. The difference between treatment groups was 13.8%, (98% CI, −4.5% to 32%) (P = .04). Adverse events were mild for both treatments. Conclusions. Miltefosine is noninferior to meglumine antimoniate for treatment of pediatric cutaneous leishmaniasis caused by Leishmania (Viannia) species. Advantages of oral administration and low toxicity favor use of miltefosine in children. Clinical Trial Registration. NCT00487253.Keywords
This publication has 36 references indexed in Scilit:
- Randomized Controlled Clinical Trial to Access Efficacy and Safety of Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania (Viannia) guyanensis in Manaus, BrazilThe American Journal of Tropical Medicine and Hygiene, 2011
- Miltefosine in the Treatment of Cutaneous Leishmaniasis Caused by Leishmania braziliensis in Brazil: A Randomized and Controlled TrialPLOS Neglected Tropical Diseases, 2010
- Efficacy of Miltefosine for the Treatment of American Cutaneous LeishmaniasisThe American Journal of Tropical Medicine and Hygiene, 2010
- Miltefosine Treatment ofLeishmania majorInfection: An Observational Study Involving Dutch Military Personnel Returning from Northern AfghanistanClinical Infectious Diseases, 2010
- Short communication: The cost‐effectiveness of cutaneous leishmaniasis patient management during an epidemic in Chaparral, Colombia in 2004Tropical Medicine & International Health, 2007
- Pharmacokinetics of Antimony in Children Treated for Leishmaniasis with Meglumine AntimoniateThe Journal of Infectious Diseases, 2007
- Oral miltefosine treatment in children with mild to moderate Indian visceral leishmaniasisThe Pediatric Infectious Disease Journal, 2003
- Domestic and peridomestic transmission of American cutaneous leishmaniasis: changing epidemiological patterns present new control opportunitiesMemórias do Instituto Oswaldo Cruz, 2001
- Miltefosine, an Oral Agent, for the Treatment of Indian Visceral LeishmaniasisNew England Journal of Medicine, 1999
- Epidemiology of Cutaneous Leishmaniasis in Colombia: Environmental and Behavioral Risk Factors for Infection, Clinical Manifestations, and PathogenicityThe Journal of Infectious Diseases, 1993